- In the context of EudraLex Volume 4 Annex 6, the term active substance gas refers to a gas that is used as the active substance of a medicinal gas product. Annex 6 specifically addresses both the manufacture of active substance gases and the manufacture of medicinal gases. Understanding this distinction is important because different parts of the EU GMP framework apply to these two stages. The European Commission states that the boundary between active substance manufacture and medicinal-product manufacture should be clearly defined in each Marketing Authorisation dossier.
- The concept can be understood by considering a medicinal gas such as oxygen. Atmospheric air may be processed through an air separation plant, producing an oxygen stream that is subsequently purified and controlled. The oxygen itself can constitute the active substance, while the later pharmaceutical operations used to manufacture the finished medicinal product may include storage, transfer, filling into approved containers, testing, labelling and certification. The precise manufacturing boundary must nevertheless be established and documented for the particular product and manufacturing process.
- Annex 6 states that, under normal circumstances, the production and purification steps of the gas belong to the manufacture of the active substance. The gas enters the pharmaceutical field from the first storage of gas intended for pharmaceutical use. This provides an important practical distinction between the production of the gas as an active substance and the subsequent manufacture of the medicinal product.
- Active substance gases may be produced by chemical synthesis or obtained from natural sources followed by purification where necessary. Annex 6 specifically gives an air separation plant as an example of obtaining gases from a natural source followed by appropriate processing. Therefore, active substance gas manufacture can encompass substantially different technologies, but the resulting gas must be appropriately controlled to ensure that it meets its established quality requirements.
- The manufacture of active substance gases is generally subject to the Basic Requirements of EU GMP Part II, together with the relevant requirements of Annex 6 and other applicable GMP annexes. This means that active substance gas manufacture is not simply treated as an ordinary industrial gas-production activity when the gas is intended to become the active substance of a medicinal product. Appropriate GMP controls must be applied to the manufacturing process according to the defined regulatory boundary.
- There is, however, a specific consideration for air separation. Annex 6 states that the requirements concerning starting materials for active substances in Part II Chapter 7 do not apply to the production of active substance gases by air separation. Instead, the manufacturer should ensure that the quality of the ambient air is suitable for the established process and that changes in ambient-air quality do not adversely affect the quality of the active substance gas. This makes control of the air source and process monitoring particularly important for gases produced by air separation.
- Continuous manufacturing is especially relevant to active substance gases because processes such as air separation can operate continuously. Annex 6 requires the production of active substance gases through a continuous process to be continuously monitored for quality, with monitoring results retained in a manner that permits trend evaluation. This approach recognises that continuous process monitoring can provide important evidence that the quality of the active substance gas remains under control over time.
- The concept of trend evaluation is particularly important for medicinal-gas manufacturers because a continuous process may produce very large quantities of gas over an extended period. Instead of relying solely on isolated testing events, appropriate process and quality data can be evaluated over time to identify changes or deterioration that could potentially affect gas quality. The monitoring strategy should therefore be designed around the critical quality characteristics and risks of the particular active substance gas.
- The distinction between active substance gas and medicinal gas becomes more complicated where the production process is continuous and there is no intermediate storage between the active-substance stage and the medicinal-product stage. Annex 6 recognises this exceptional situation and states that, where intermediate storage is not possible, the whole process—from the starting materials of the active substance through to the medicinal finished product—should be considered to belong to the pharmaceutical field. This arrangement should be clearly stated in the Marketing Authorisation dossier.
- This means that the physical manufacturing process does not always have to be divided into two completely separate factories or production systems. The regulatory boundary is determined by the documented manufacturing process and the applicable GMP requirements, rather than simply by the physical location of equipment. A manufacturer therefore needs a clear understanding of where active-substance manufacture ends and medicinal-product manufacture begins.
- Another important aspect is the storage of active substance gas. Annex 6 states that gases enter the pharmaceutical field from the first storage of gas intended for such use. This point is significant because storage can represent the transition from the industrial production of the gas to its use within the pharmaceutical manufacturing process. Appropriate controls over storage, identification, quality status, contamination prevention and traceability therefore become essential.
- Active substance gases may also be transferred or delivered in bulk. Annex 6 requires transfers and deliveries of active substance gases in bulk to comply with the relevant requirements specified later in the Annex for medicinal gases. This means that controls relating to transfer operations, contamination prevention, equipment, connections and handling remain important even when the gas has not yet reached the final medicinal-product presentation.
- The filling of active substance gases into cylinders or mobile cryogenic vessels is another area where Annex 6 creates a direct connection between active-substance manufacture and medicinal-gas manufacturing requirements. The Annex states that such filling should comply with the relevant medicinal-gas filling requirements as well as Part II Chapter 9. Consequently, active substance gas filling is not simply an ordinary industrial filling operation; it requires appropriate controls for the pharmaceutical context.
- The use of cylinders and mobile cryogenic vessels creates particular contamination and mix-up risks. Although medicinal-gas manufacturing is generally performed in closed equipment and environmental contamination may therefore be relatively low, Annex 6 specifically recognises the possibility of contamination and cross-contamination with other gases, particularly because containers may be reused. This is why container identification, preparation, maintenance, cleaning, filling and traceability are important elements of the overall control strategy.
- The distinction between an active substance gas and a finished medicinal gas should also be reflected in the Pharmaceutical Quality System and associated documentation. The manufacturing process, specifications, responsibilities, quality controls and interfaces between the active-substance and medicinal-product stages should be clearly defined. Documentation should provide sufficient evidence that each stage has been performed according to the approved process and applicable GMP requirements.
- The Marketing Authorisation dossier therefore plays a particularly important role. It should clearly establish the manufacturing boundary and describe the relevant manufacturing steps. This is not merely an administrative distinction. The defined boundary determines which GMP requirements apply to the different operations and provides a regulatory basis for inspection, validation, quality control and batch certification.
- A useful way to visualise the concept is as a manufacturing chain: source or starting material → production of active substance gas → purification → active substance gas storage → transfer → medicinal-product manufacture → filling → testing → certification and release → distribution. The exact sequence will vary according to the gas and manufacturing technology, but the regulatory principle is that the boundary between the active substance and finished medicinal product must be clearly defined and justified.
- For oxygen produced by an air separation process, for example, ambient air is introduced into the production system and subjected to appropriate separation and purification operations. The resulting oxygen can become the active substance gas. Once the gas enters the pharmaceutical manufacturing stage, additional controls may apply to its storage, transfer, filling, testing, documentation, labelling and release as a medicinal product. The specific process boundary should be defined in the relevant Marketing Authorisation documentation.
- The same general principle can apply to other medicinal gas mixtures. Where individual gases are used as components of a medicinal product, it is important to understand whether a particular gas is itself an active substance, a component of an active-substance mixture, or part of the finished medicinal product manufacturing process. The manufacturing and control strategy should reflect the approved composition and manufacturing process.
- Quality control of active substance gases is another important consideration. Continuous processes should be appropriately monitored, and the resulting data should be retained so that trends can be evaluated. The manufacturer should establish suitable specifications and analytical controls based on the identity, purity, impurities and other critical quality attributes relevant to the particular gas and its intended medicinal use.
- Process validation is also important because active substance gas production may involve complex and highly controlled physical or chemical processes. The validation strategy should demonstrate that the manufacturing process is capable of consistently producing gas that meets the established quality requirements. For continuous processes, process understanding and ongoing monitoring are particularly important because process performance can vary over time.
- The control of impurities is a fundamental element of active substance gas manufacture. Depending on the production technology, potential impurities may originate from starting materials, ambient air, process equipment, lubricants, cleaning agents, maintenance activities, cross-connections or other sources. The manufacturer should understand the potential impurity profile and establish appropriate controls to ensure that the active substance gas remains suitable for its intended pharmaceutical use.
- Cross-contamination control is equally important where manufacturing facilities handle more than one gas. Annex 6 contains specific requirements intended to prevent the incorrect gas from being introduced into a system or container. Equipment should be designed to ensure that the correct gas is filled into the correct container, and cross-connections between pipelines carrying different gases should normally be avoided. Where cross-connections are necessary, appropriate qualification should demonstrate that there is no unacceptable risk of cross-contamination.
- The management of gas-specific connections is therefore an important technical control. Filling manifolds should use appropriate connections, and the use of different connection standards or adaptors at the same site should be carefully controlled. These controls are particularly important because a wrong-gas connection can potentially result in a serious product mix-up.
- The traceability of active substance gases and medicinal gases is also important. For packaged medicinal gases, cylinders consist of reusable shells and valves, and the EMA specifically notes that additional information concerning the use and maintenance of these reusable components may be necessary to ensure adequate traceability.
- It is also important to distinguish active substance gases from non-medicinal process or utility gases. A gas used in a manufacturing facility does not automatically become an active substance simply because it is present in the production environment. The term active substance gas applies to the gas that forms the active substance of the medicinal product. Other gases may serve technical, processing or utility purposes and are controlled according to their intended use and associated risks.
- The active substance concept also helps explain why Annex 6 interacts with both EU GMP Part II and Part I. Active substance gas manufacture follows the applicable principles of Part II, while medicinal-gas manufacture follows the applicable requirements of Part I, together with the specific provisions of Annex 6. The regulatory framework therefore follows the nature and stage of manufacture rather than treating every operation involving gas as identical.
- From a practical GMP perspective, manufacturers should establish a clear manufacturing flow diagram showing where active substance manufacture starts and ends, where pharmaceutical manufacture begins, where storage occurs, and where the gas becomes part of the finished medicinal product process. This diagram should be consistent with the Marketing Authorisation dossier, manufacturing instructions, validation documentation and quality agreements where applicable.
- The concept is particularly important during GMP inspections. Inspectors need to understand which parts of the manufacturing operation are subject to Part II requirements and which are subject to Part I requirements. An unclear or inconsistent definition of the manufacturing boundary can create uncertainty regarding responsibilities, documentation, validation, quality control and regulatory compliance.
- The distinction is also relevant to outsourced activities. Where purification, storage, testing, maintenance, cylinder preparation or other activities are performed by another organisation, the responsibilities of each party should be clearly established. Technical and quality agreements should ensure that the quality of the active substance gas is maintained throughout the relevant supply chain and manufacturing process.
- Another important consideration is the relationship between active substance manufacture and Qualified Person (QP) certification. The QP is responsible for certification of medicinal-product batches in accordance with the applicable EU GMP and Marketing Authorisation requirements. The active substance stage provides critical input into the quality of the finished medicinal gas, but the precise responsibilities at the interface should be clearly defined within the pharmaceutical quality system.
- The current regulatory environment should also be considered when interpreting Annex 6. The European Commission currently lists Annex 6 as Manufacture of Medicinal Gases within EudraLex Volume 4. At the same time, EMA and PIC/S have initiated work to revise Annex 6. The EMA concept paper states that the proposed guideline is intended to replace the existing EudraLex Volume 4 Annex 6, so organisations should monitor the regulatory status of the revision when developing or updating medicinal-gas GMP procedures.
- In summary, an active substance gas is the medicinally active gas that serves as the active substance of a medicinal gas product. Under Annex 6, its production and purification normally belong to the active-substance manufacturing stage, while subsequent pharmaceutical operations belong to medicinal-product manufacture. The boundary must be clearly defined in the Marketing Authorisation dossier, and special arrangements apply to continuous processes where no intermediate storage exists.
- Understanding this distinction provides the foundation for interpreting many other Annex 6 requirements, including air separation, gas purification, continuous manufacturing, process monitoring, bulk gas transfer, cylinder filling, cryogenic vessel filling, contamination control, quality control, process validation, traceability, documentation, and Qualified Person certification. Each of these areas can be examined separately to understand how GMP principles are applied throughout the medicinal-gas manufacturing lifecycle.
